Angle’s JNJ-trumping liquid biopsy system could see five-fold jump in near-term sales
This article was originally published in Clinica
Executive Summary
Angle plc began developing its circulating tumor cell capture system, Parsortix only in 2011, but the company is now moving into the commercialization phase and expecting a sharp sales ramp-up over the next couple of years.